Boston Scientific to Acquire Penumbra in $14.5bn Medtech Mega-Deal
Boston Scientific agreed to acquire Penumbra for $14.5bn at the J.P. Morgan Healthcare conference, marking this year’s largest medtech megadeal. EY reports medtech volumes rising mid-to-high single digits with stable pricing and deal-making remaining judicious despite geopolitical supply chain concerns.
1. Acquisition at J.P. Morgan Conference
Boston Scientific agreed to acquire Penumbra for $14.5 billion during the J.P. Morgan Healthcare conference in January 2026, making it the largest medtech transaction of the year. Shareholders will review the deal structure and expected synergies as part of the closing process.
2. Industry Volume and Pricing Trends
EY’s latest report highlights mid-to-high-single-digit growth in medtech procedure volumes alongside stable pricing, signalling robust demand across key markets. These fundamentals underpin valuations even as capital markets remain selective.
3. M&A and IPO Activity
After a modest IPO resurgence in 2025—including MiniMed’s $560 million raise—2026 deal-making has been judicious, with fewer but higher-valued transactions. Notable deals include Medtronic’s acquisition of Scientia Vascular, reflecting strategic portfolio expansions.
4. Geopolitical and Supply Chain Factors
Tensions in the Middle East have directly impacted 2%–3% of global medtech sales to date, with potential downstream risks in semiconductor and electronics supply chains. Companies are monitoring costs and procedural timelines for any ripple effects.